{"nctId":"NCT00074412","briefTitle":"Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding","startDateStruct":{"date":"2007-01"},"conditions":["HIV Infections"],"count":2026,"armGroups":[{"label":"2A","type":"EXPERIMENTAL","interventionNames":["Drug: Nevirapine"]},{"label":"2B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Nevirapine placebo"]}],"interventions":[{"name":"Nevirapine","otherNames":["NVP"]},{"name":"Nevirapine placebo","otherNames":["NVP placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Note: As of 08/10/07, the arm assignments for current and new participants have changed. Please see the above description for this trial for more information.\n\nInclusion Criteria for Mothers:\n\n* 18 years of age or older\n* HIV infected\n* In third trimester of pregnancy, or at most 3 days post-delivery\n* If baby is not yet born, planning to deliver at a facility where the study is being conducted\n* Plan to breastfeed\n\nExclusion Criteria for Mothers:\n\n* Complications with this pregnancy\n* Serious medical condition that would interfere with the study (e.g., that would prevent breastfeeding or adherence to the follow-up schedule), as judged by the on-site clinician\n\nInclusion Criteria for Infants:\n\n* Born to an HIV infected mother who is eligible for the study\n* Weighed at least 2000 grams (4.4 lbs) at birth\n* Blood sample obtained from the infant for HIV-1 DNA PCR, CBC with differential, and ALT\n* Infants in a multiple birth are eligible only if both/all infants are eligible for the study and assigned to the same study group\n* Able to breastfeed (e.g., mother and infant alive with no condition apparent that would prevent breastfeeding)\n\nExclusion Criteria for Infants:\n\n* HIV DNA PCR positive at birth\n* ALT of Grade 2 or higher at birth\n* Hemoglobin, absolute neutrophil count, or platelet count of Grade 3 or higher at birth\n* Skin rash of Grade 2B (urticaria), Grade 3, or above\n* Confirmed or suspected clinical hepatitis\n* Serious illness or condition that would interfere with compliance with study procedures","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"700","spread":null},{"groupId":"OG001","value":"699","spread":null}]}]}]},{"type":"PRIMARY","title":"Frequency and Severity of Adverse Reactions Among Participating Infants","description":"For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"375","spread":null},{"groupId":"OG001","value":"332","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"694","spread":null},{"groupId":"OG001","value":"677","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"832","spread":null},{"groupId":"OG001","value":"838","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"689","spread":null},{"groupId":"OG001","value":"683","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"629","spread":null},{"groupId":"OG001","value":"616","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Rates of HIV Infection in the Two Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"664","spread":null},{"groupId":"OG001","value":"663","spread":null}]}]}]},{"type":"SECONDARY","title":"Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"678","spread":null},{"groupId":"OG001","value":"684","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":152,"n":758},"commonTop":["Gastroenteritis","Upper respiratory infection","Neutrophil count decreased","Malaria","Oral candidiasis"]}}}